Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridyl SCHEMBL4596384 | 0.92 | KDM4E (0.56) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL19009473 | 0.83 | HPGDS (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL199273 | 0.83 | PLAU (0.60) | KDM4ELMNACYP1A2NPC1L3MBTL1 | |
| SCHEMBL29923403 | 0.83 | PLAU (0.60) | KDM4ELMNACYP1A2NPC1L3MBTL1 | |
| SCHEMBL30522769 | 0.81 | PLAU (0.58) | KDM4ELMNACYP1A2NPC1L3MBTL1 | |
| SCHEMBL13154459 | 0.80 | KDM4E (0.55) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL27333822 | 0.79 | KDM4E (0.45) | KDM4ELMNACYP1A2NPC1L3MBTL1 | |
| SCHEMBL12223316 | 0.79 | PLAU (0.56) | KDM4ELMNACYP1A2NPC1L3MBTL1 | |
| SCHEMBL13978866 | 0.79 | PLAU (0.56) | KDM4ELMNACYP1A2NPC1L3MBTL1 | |
| SCHEMBL24518501 | 0.78 | MAPT (0.44) | KDM4ELMNACYP1A2NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076857-A1 | EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY | CARIBOU BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| CN-101570536-A | Anthracene-based compound and organic light emitting device employing the same | SAMSUNG ELECTRONICS CO LTD (KR) | 2009-11-04 | — | — | CN | claimed |
| JP-64003169-A | — | — | None | — | — | JP | disclosed |
| CN-112689511-A | Compositions comprising minicells of bacterial origin and methods of use thereof | 安吉尼科分子传输公司 | 2021-04-20 | — | — | CN | disclosed |
| US-10781226-B2 | Photoactivatable cancer prodrug | TEXAS STATE UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200239503-A1 | PHOTOACTIVATABLE CANCER PRODRUG | TEXAS STATE UNIVERSITY | 2020-07-30 | — | — | US | disclosed |
| US-20200054647-A1 | RUTHENIUM COMPLEXES FOR TREATING CANCER WHICH COMPRISES CANCER STEM CELLS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2020-02-20 | — | — | US | disclosed |
| EP-3539971-A1 | RUTHENIUM COMPLEXES FOR TREATING CANCER WHICH COMPRISES CANCER STEM CELLS | Universidade de Santiago de Compostela (ES) | 2019-09-18 | — | — | EP | disclosed |
| WO-2019078871-A1 | PHOTOACTIVATABLE CANCER PRODRUG | TEXAS STATE UNIVERSITY (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2018087413-A1 | RUTHENIUM COMPLEXES FOR TREATING CANCER WHICH COMPRISES CANCER STEM CELLS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2018-05-17 | — | — | WO | disclosed |
| CN-105340100-B | Organic electroluminescent device heterocyclic compound and application thereof | 东曹株式会社 | 2018-01-30 | — | — | CN | disclosed |
| US-7413818-B2 | Light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7279233-B2 | Light-emitting material and light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279233-B2 | Light-emitting material and light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | disclosed |
| EP-1667979-A4 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1667979-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6929873-B2 | Electroluminescent device using metal coordination compound | CANON KABUSHIKI KAISHA (JP) | 2005-08-16 | — | — | US | disclosed |
| WO-2005030130-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040013905-A1 | Electroluminescent device using metal coordination compound | CANON KABUSHIKI KAISHA (JP) | 2004-01-22 | — | — | US | disclosed |
| JP-S643169-A | PRODUCTION OF HETEROCYCLIC COMPOUND | WAKO PURE CHEM IND LTD | 1989-01-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781226-B2 | Photoactivatable cancer prodrug | UGT1A7, DCPS, PPOX | KDM4E 2483/4885LMNA 2803/4885CCR1 4203/4885 |
| US-20200054647-A1 | RUTHENIUM COMPLEXES FOR TREATING CANCER WHICH COMPRISES CANCER STEM CELLS | MYC, MYCBP, MCL1 | KDM4E 2445/4885LMNA 3613/4885CCR1 3259/4885 |
| US-20200239503-A1 | PHOTOACTIVATABLE CANCER PRODRUG | UGT1A7, DCPS, PPOX | KDM4E 2483/4885LMNA 2803/4885CCR1 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.